The Emerging Role of Nrf2 in Heart Failure: From Cardioprotection to Therapeutic Approaches
ESC Heart Failure · 01.12.2025 · 12 (6) · 4000-4020
DOI: 10.1002/ehf2.15406 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ESC Heart Failure, online erschienen am 08.09.2025. Verfasst von Emiliano Fiori und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Center, AZORG, Aalst, Belgium. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Heart Failure, Oxidative Stress, Cardiotonic Agents. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 169 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Heart failure (HF) is a multifactorial and pathophysiological complex syndrome, involving not only neurohormonal activation but also oxidative stress, chronic low-grade inflammation, and metabolic derangements. Central to the cellular defence against oxidative damage is nuclear factor erythroid 2-related factor 2 (Nrf2), a transcription factor that orchestrates antioxidant and cytoprotective responses. Preclinical in vitro and in vivo studies reveal that Nrf2 signalling is consistently impaired in HF, contributing to the progression of myocardial dysfunction. The loss of Nrf2 activity intersects a complex network of pathological processes involving neurohormonal activation, ischaemia–reperfusion injury, and sustained inflammation, exacerbating cardiac functional decline. Nrf2 deficiency diminishes resilience to clinical conditions such as hypertension, diabetic cardiomyopathy, and cancer therapy-related cardiotoxicity, favouring the transition from initial cardiac dysfunction to overt HF. Initial evidence supports the therapeutic potential of Nrf2 modulation. Lifestyle interventions such as exercise training, various natural compounds, and established cardiovascular agents (e.g. sodium-glucose cotransporter-2 inhibitors) have been shown to restore Nrf2 activity. This review analyses the emerging role of Nrf2 as both a key player in HF pathogenesis and a promising therapeutic target, highlighting available evidence across HF phenotypes and addressing the controversies surrounding its pharmacological modulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular Center, AZORG, Aalst, Belgium.
- Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.
- Department of Medicine and Health Sciences "V. Tiberio", University of Molise, Campobasso, Italy.
- Institute of Medicine and Sport Science, National Italian Olympic Committee, Rome, Italy.
- Cardiology Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Roma, Rome, Italy.
- Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University, Rome, Italy.
ORCID-Profile: Emiliano Fiori
Zitieren
APA
Fiori, E., Davinelli, S., Ferrera, A., Medoro, A., Barsali, C., Battistoni, A., Volterrani, M., Volpe, M., Saso, L., & Rubattu, S. (2025). The Emerging Role of Nrf2 in Heart Failure: From Cardioprotection to Therapeutic Approaches. ESC Heart Failure, 12(6), 4000-4020. https://doi.org/10.1002/ehf2.15406
Vancouver
Fiori E, Davinelli S, Ferrera A, Medoro A, Barsali C, Battistoni A, et al. The Emerging Role of Nrf2 in Heart Failure: From Cardioprotection to Therapeutic Approaches. ESC Heart Failure. 2025;12(6):4000-4020. doi:10.1002/ehf2.15406
BibTeX
@article{Fiori2025,
author = {Fiori, Emiliano and Davinelli, Sergio and Ferrera, Armando and Medoro, Alessandro and Barsali, Carlo and Battistoni, Allegra and Volterrani, Maurizio and Volpe, Massimo and Saso, Luciano and Rubattu, Speranza},
title = {The Emerging Role of Nrf2 in Heart Failure: From Cardioprotection to Therapeutic Approaches},
journal = {ESC Heart Failure},
year = {2025},
volume = {12},
number = {6},
pages = {4000--4020},
doi = {10.1002/ehf2.15406}
}
EUVIMED